News >

Update Shows Depth of Darolutamide Benefit in Nonmetastatic CRPC

Caroline Seymour
Published: Thursday, Jun 27, 2019

Karim Fizazi, MD, PhD

Karim Fizazi, MD, PhD
In addition to improving metastasis-free survival (MFS), the combination of darolutamide and androgen deprivation therapy (ADT) maintains quality of life (QoL) and delays pain progression1 in patients with nonmetastatic castration-resistant prostate cancer (CRPC) compared with ADT alone, said Karim Fizazi, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication